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In healthy individuals, immune-checkpoint molecules prevent autoimmune responses and 
limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules 
to evade eradication by the immune system. Over the past years, immune-checkpoint  
blockade of cytotoxic T lymphocyte antigen-4 and programed death-1 emerged as 
promising strategies to activate antitumor cytotoxic T cell responses. Although com-
plete regression and long-term survival is achieved in some patients, not all patients 
respond. This review describes promising, novel combination approaches involving 
immune-checkpoint blockade in the context of the cancer-immunity cycle, aimed at 
increasing response rates to the single treatments. Specifically, we discuss combinations 
that promote antigen release and presentation, that further amplify T cell activation, that 
inhibit trafficking of regulatory T cells or MSDCs, that stimulate intratumoral T cell infiltra-
tion, that increase cancer recognition by T cells, and that stimulate tumor killing.
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iNTRODUCTiON
Historically, the importance of the immune system in restraining cancer development has been 
demonstrated by the observation that immune-deficient patients and organ-transplant recipients 
treated with immunosuppressive drugs have an increased risk to develop cancer (1). The steps 
involved in the development and maintenance of tumor immunity were recently conceptualized in 
the “cancer-immunity” cycle (and schematically depicted in Figure 1, outer circle) (2). This cycle 
describes the steps that are required to generate tumor-specific cytotoxic T lymphocytes [CTLs, also 
known as CD8+ (effector) T cells] that are capable of killing tumor cells. Defects/impediments in 
Abbreviations: 1MT, 1-methyl-d-tryptophan; ACT, adoptive cell transfer; APC, antigen-presenting cell; BRAFi, BRAF 
inhibitor; CARs, chimeric antigen receptors; CD, cluster of differentiation; CR, complete response; CRPC, castration-resistant 
prostate cancer; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T lymphocyte antigen-4; CXCL, C–X–C motif chemokine 
ligand; GITR, glucocorticoid-induced TNFR family-related gene; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; gp100, glycoprotein 100; GVAX, cellular vaccines consisting of irradiated GM-CSF producing tumor cells; HNSCC, 
head and neck squamous cell carcinoma; HPV, human papillomavirus; ICD, immunogenic cell death; IDO, indoleamine 
2,3-dioxygenase; IFN-γ, interferon gamma; KIRs, killer-cell immunoglobulin-like receptors; LAG-3, lymphocyte-activation 
gene-3; MAPK, mitogen-activated protein kinases; MART-1, protein melan-A; MEKi, mitogen-activated protein kinase 
kinase inhibitor; MHC, major histocompatibility complex; NCT, national clinical trial; NK cell, natural killer cell; NSCLC, 
non-small-cell lung carcinoma; NY-ESO-1, cancer-testis antigen; ORR, overall response rate; OS, overall survival; PD-1, 
programed death-1; PD-L1,2, programed death-ligand 1,2; PFS, progression-free survival; PSA, prostate-specific antigen; 
PTEN, phosphatase and tensin homolog; RCC, renal cell carcinoma; SLP, synthetic long peptide; TCR, T cell receptor; TG, 
tumor growth; TIGIT, T cell ITIM domain; TIL, tumor-infiltrating lymphocyte; TIM-3, T cell immunoglobulin and mucin 
domain-3; TNFR, tumor necrosis factor receptor; Treg, regulatory T cell; TV, tumor volume; VEGF, vascular endothelial 
growth factor; VEGFR, VEGF receptor.
FigURe 1 | Clinical efficacy of combination approaches with anti-CTLA-4 depicted in the cancer-immunity cycle. In order to enhance the response rate 
of immune-checkpoint blockade, anti-CTLA-4 can be combined with therapies that promote various steps of the cancer-immunity cycle. Arrow size indicates the 
efficacy increase compared to anti-CTLA-4 monotherapy in clinical and preclinical studies. Clinical response rates or OS data compared to anti-CTLA-4 only for the 
treatment of melanoma patients are annotated between brackets. Abbreviations: A2ARa, adenosine 2a receptor antagonist; ACT, adoptive cell transfer; BRAFi, 
BRAFV600E inhibitors; GVAX, cellular vaccines consisting of irradiated GMCSF-producing tumor cells; IDOi, IDO inhibitor; MEKi, MEK inhibitors; OS, overall survival; 
TLR9a, TLR9 agonist.
2
Swart et al. Combinations with Immune-Checkpoint Blockade
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 233
the cycle due to inhibitory receptor signaling frequently lead to 
evasion of tumor eradication by the immune system. This may 
explain the clinical success of immune-checkpoint therapies. 
Two important immune-checkpoint molecules include cytotoxic 
T lymphocyte antigen-4 (CTLA-4, also known as CD152) and 
programed death-1 (PD-1, also known as CD279).
Cytotoxic T Lymphocyte Antigen-4
Like CD28, CTLA-4 binds to the co-stimulatory molecules CD80 
or CD86, but instead attenuates T cell activation (3). Therefore, 
CTLA-4 mainly exerts its immunosuppressive effect during 
activation in secondary lymphoid organs (Figure  2A) (4, 5). 
However, CTLA-4 signaling also enhances immunosuppres-
sion in other ways, e.g., by promoting the activity of regulatory 
T  cells (Tregs) inside the tumor-microenvironment (6, 7), and 
the relative importance of these different mechanisms is not fully 
understood nor their contribution to therapy success. The anti-
CTLA-4 monoclonal antibody ipilimumab (fully human IgG1, 
Bristol-Myers Squibb) increased the median overall survival 
(OS) among metastatic melanoma patients in a pooled analysis 
of phase II and III data and some patients even survived 10 years 
after treatment (8). However, 60% of the patients treated with 
anti-CTLA-4 experienced immune-related adverse events, which 
were severe (grade 3 or 4) in 10–15% of the patients (9).
FigURe 2 | Simplified mechanism of action CTLA-4 and PD-1. Both CTLA-4 (A) and PD-1 (B) inhibit T cell activation in secondary organs after interaction with 
respectively B7 or PD-L1 and PD-L2. However, PD-1 also inhibits T cell responses after interaction with PD-L1 on tumor cells, and PD-1 expressed by a specific 
subset of tumor cells also contributes directly to tumorigenesis upon interaction with PD-L1 on tumor cells or stroma cells. Abbreviations: APC, antigen-presenting 
cell; CD, cluster of differentiation; CTLA-4, cytotoxic T lymphocyte antigen-4; MHC-p, peptide-major-histocompatibility complex; PD-1, programed death-1; PD-L1, 
programed death-ligand-1; TCR, T cell receptor. Note that the scheme is highly simplified: in reality CTLA-4 and PD-1 act through multiple mechanisms.
3
Swart et al. Combinations with Immune-Checkpoint Blockade
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 233
Anti-CTLA-4 treatment has also been studied in non-
melanoma tumors, demonstrating an 8% partial response rate in 
patients with metastatic renal cell carcinoma (RCC) in a phase II 
study (10). Nevertheless, anti-CTLA-4 treatment is generally not 
effective in non-melanoma tumors, which might for instance be 
due to a low fraction of tumor-reactive T cells in these tumors, 
high expression of PD-L1, or the secretion of anti-inflammatory 
cytokines. Overall, long-term survival can be obtained with anti-
CTLA-4 treatment in melanoma patients, but the toxicity is quite 
high and it is typically less effective in other tumor types.
Programed Death-1
Similar to CTLA-4, PD-1 signaling within secondary lymphoid 
organs impairs T cell priming and enhances differentiation 
into Tregs (11, 12). Moreover, because PD-L1 expression 
is frequently upregulated in cancers and tumor-infiltrating 
lymphocytes (TILs) can express high levels of PD-1 (4, 13), 
PD-1 inhibits T cell responses in the tumor. PD-1 can also be 
expressed on tumor cells, such as melanoma subpopulations, 
and contribute to tumorigenesis (14). Therefore, a part of the 
efficacy of anti-PD-1 therapy may be due to inhibition of this 
cell-intrinsic pathway active in some tumor cells (Figure  2B) 
(14). As expected from the predominantly peripheral role of 
PD-1, Pdcd1−/− (the gene encoding for PD-1) mice developed 
mild, organ-specific autoimmune responses (15, 16). Large 
phase I studies led to the prompt approval of the anti-PD-1 
monoclonal antibodies pembrolizumab (humanized IgG4, 
Merck) and nivolumab (fully human IgG4, Bristol-Myers 
Squibb, Ono Pharmaceuticals) for patients with unresectable or 
metastatic melanoma not responding to anti-CTLA-4 (17–19). 
Importantly, anti-PD-1 was superior to anti-CTLA-4 in the 
treatment of advanced melanoma in terms of progression-free 
survival (PFS; 47.3 versus 26.5%) (20). Because severe (grade 
3–5) side effects also occurred less frequently in anti-PD-1-
treated (13.3%) compared with anti-CTLA-4-treated patients 
(19.9%), anti-PD-1 treatment is currently the first-line treatment 
for unresectable or metastatic melanoma in the USA and the EU. 
In addition, the FDA approved anti-PD-1 for the treatment of 
Hodgkin lymphoma, non-small-cell lung carcinoma (NSCLC), 
RCC, and head and neck squamous cell carcinoma (HNSCC), 
because clinical trials demonstrated the safety and efficacy in 
these cancer types (21–26). Anti-PD-1 might also improve the 
treatment of bladder, gastric, ovarian, and triple negative breast 
cancer (4, 19). Furthermore, anti-PD-L1 (atezolizumab) was 
recently approved for the treatment of bladder cancer (urothelial 
carcinoma) (27). In summary, anti-PD-1 is less toxic yet more 
effective than anti-CTLA-4 and is also effective in the treatment 
of non-melanoma tumors.
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iMPROviNg TUMOR RegReSSiON UPON 
CTLA-4 OR PD-1 BLOCKADe
Despite the general success of checkpoint therapies, not all 
patients respond or achieve only partial tumor regression to 
anti-PD-1 or anti-CTLA-4 monotherapy (20). This is probably 
due to impediments somewhere in the cancer-immunity cycle 
(Figure 1): release of cancer antigens (step 1), antigen presenta-
tion (step 2), T cell priming and activation (step 3), T cell traf-
ficking to tumors [step 4; note that, in this review, we specifically 
consider blocking the trafficking of immunosuppressive Tregs 
and myeloid-derived suppressor cells (MDSCs)], T cell infiltra-
tion into the tumor (step 5), cancer cell recognition by T cells 
(step 6), and killing of tumor cells (step 7). Therefore, higher 
response rates may be achieved using combination approaches of 
anti-PD-1 or anti-CTLA-4 with therapies that stimulate various 
steps of the cancer-immunity cycle, which we will discuss in this 
review. In brief, this involves combinations with conventional 
(e.g., chemotherapy and radiotherapy) and targeted therapies 
to promote antigen release (step 1) (28); combinations with 
vaccination to promote antigen presentation (step 2); combina-
tions with agonists for co-stimulatory molecules or blockade of 
co-inhibitory molecules to further amplify T cell activation (step 
3); combinations with trafficking inhibition of Tregs or MSDCs 
(step 4); combinations with anti-vascular endothelial growth fac-
tor (VEGF) to stimulate intratumoral T cell infiltration (step 5); 
combinations with adoptive cell transfer (ACT) to increase cancer 
recognition by T cells (step 6); and combinations that stimulate 
tumor killing (step 7). Finally, individualized treatment, based 
on biomarkers that predict clinical responses, could potentially 
optimize the management of various cancer types (29). In the fol-
lowing, we will discuss the progress with respect to the mentioned 
combination strategies step by step.
COMBiNATiONS wiTH STiMULATiON 
OF ANTigeN ReLeASe AND DANgeR 
SigNALS (STeP 1)
Chemotherapy, targeted therapies, and radiotherapy can promote 
immunogenic cell death (ICD) of tumor cells. ICD results in the 
release of tumor antigens and “danger signals,” also known as 
damage-associated molecular patterns (DAMPS), such as cal-
reticulin, ATP, type I IFN, and non-histone chromatin-binding 
protein high-mobility group box 1 (HMGB1) (30, 31). Binding 
to their receptors (CD91, the purinergic receptors P2RX7 and 
P2RY2, IFNAR, and the toll-like receptor TLR4, respectively) 
on DCs, results in their activation, enhanced antigen presenta-
tion, upregulation of co-stimulatory receptors, and induction 
of adaptive immune responses (32), whereas cell death that is 
“immunologically silent” induces tolerance.
Chemotherapy
Promising preclinical studies have shown that chemotherapy 
can indeed sensitize tumors to immune-checkpoint blockade by 
promoting T cell activation and infiltration into the tumor (33). 
Moreover, chemotherapy, such as by cisplatin, can also enhance 
responses to T cell based immune therapies by sensitizing the 
tumor cells to T cell-induced death rather than by ICD (34). For 
example, cisplatin has been shown to synergize with synthetic 
long peptide (SLP) vaccination and improve tumor-cell killing 
in a preclinical tumor model (35). With respect to the clinical 
application, chemotherapy (dacarbazine) combined with anti-
CTLA-4 (ipilimumab) was first tested in metastatic melanoma 
patients. A phase II study showed that more patients responded to 
dacarbazine plus anti-CTLA-4 when compared to anti-CTLA-4 
alone (14.3 versus 5.4%) (36). In addition, a phase III study dem-
onstrated that this combination slightly increased the OS, when 
compared to dacarbazine alone (11.2 versus 9.1  months) (37) 
(note the difference between the latter two studies in terms of the 
monotherapy). However, immune-related severe adverse events 
(grade 3 or 4) also increased (56.3 versus 27.5%) (37).
Since chemotherapeutics promote antigen release and may 
promote the activation of tumor-specific T cells, combined 
chemotherapy and immune-checkpoint blockade may also be 
clinically effective in non-melanoma tumors. However, chemo-
therapy (paclitaxel and carboplatin) followed by anti-CTLA-4 
(ipilimumab) resulted in only a minor increase of the immune-
related PFS in a phase II and phase IIIb/IV study in NSCLC and 
extensive disease SCLC patients, compared with chemotherapy 
alone (38, 39). In conclusion, despite promising preclinical stud-
ies, combination therapies of immune-checkpoint blockade with 
chemotherapy have so far only slightly enhanced the clinical effi-
cacy, while amplifying adverse effects. The lack of efficacy might 
be attributed to limited induction of ICD by chemotherapy. As 
ATP is thought to be important in the recruitment and activation 
of DCs during ICD, combinations of chemotherapy and inhibi-
tion of the ATP degrading enzyme CD39 followed by immune-
checkpoint blockade might improve the clinical efficacy (40, 41).
Targeted Therapies
Targeted therapies can also restore T cell activation, but subse-
quent expression of PD-L1 on tumor cells can lead to immune 
escape. For example, clinical data demonstrated that such escape 
occurred within 10–14  days after BRAF inhibition in tumors 
of patients with metastatic melanoma (42). Thus, combination 
approaches with immune-checkpoint blockade may function 
synergistically. However, a phase I trial combining BRAFV600E 
inhibitor vemurafenib with anti-CTLA-4 (ipilimumab) in meta-
static melanoma was halted due to severe hepatotoxicity (43). To 
date, such hepatoxity did not occur in an ongoing phase I trial 
with the BRAFV600E inhibitor dabrafenib in combination with 
anti-CTLA-4 (ipilimumab) (44, 45), but clinical efficacy data are 
not yet available. Because PD-L1 is upregulated on tumor cells 
following BRAF inhibition, and anti-PD-1 therapy is less toxic 
compared to anti-CTLA-4, combining BRAFV600E inhibitors with 
anti-PD-1 therapy seems promising. Indeed, preclinical data 
showed that the combination of anti-PD-1 or anti-PD-L1 with 
BRAF inhibition enhanced antitumor responses in a BRAF/
PTEN inducible melanoma model (46), thus warranting clinical 
studies. Still, BRAFV600E inhibition can potentially lead to activa-
tion of MAPK signaling in T cells, since wild-type BRAF is not 
inhibited. This may result in exhaustion or enhance immune 
suppression (47).
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Until recently, the preclinical and clinical assessment of 
MEK inhibitors (e.g., tramatinib) in combination with immune-
checkpoint blockade was limited, because MEK inhibitors 
disrupt T cell function transiently in vitro (48). Nevertheless, a 
synergistic effect of trametinib plus anti-PD-1, anti-PD-L1, or 
anti-CTLA-4 was observed in the preclinical CT26 carcinoma 
model (49). Triple therapy with MEK inhibitors, BRAFV600E 
inhibitors, and anti-CTLA-4 may potentially optimize anti-
tumor T cell responses with limited autoimmune side effects, 
since the additional MEK inhibitors might circumvent T cell 
hyper-activation caused by BRAF inhibition (47). Nevertheless, 
the combination of MEK inhibitors (trametinib), BRAFV600E 
inhibitors (dabrafenib), and anti-CTLA-4 (ipilimumab) resulted 
in severe gastrointestinal toxicity in patients with metastatic 
melanoma in a phase I/II study (45). In contrast, MEK inhibi-
tors (trametinib) and BRAFV600E inhibitors (dabrafenib) have 
been successfully combined with anti-PD-L1 (durvalumab; 
MEDI4736) in melanoma patients in a phase I study (50). Thus, 
MEK or BRAFV600E inhibitors might be safely and effectively used 
in combination with anti-PD-L1, but little clinical efficacy data 
are currently available.
Radiotherapy
Radiotherapy induces local tumor cell death, but can also 
modulate local and systemic immunity, in essence acting as an 
in situ vaccine. Radiotherapy can promote CD8+ T cell responses 
to radiotherapy-induced peptides (51), natural (52, 53) or exog-
enous tumor antigens (54, 55), or by promoting immune control 
within the tumor-microenvironment (51, 56–58) [reviewed in 
Ref. (59)]. CD8+ T cells can contribute to radiotherapy-induced 
reduction of the primary tumor (55), and radiotherapy can 
even induce regression of lesions that reside outside the field of 
radiotherapy, called the “abscopal effect.” However, this is a very 
rare phenomenon, reported 34 times since 1969 [reviewed in Ref. 
(60)], indicating that radiotherapy alone sub-optimally engages 
the cancer-immunity cycle (or does not overrule all the impedi-
ments that may still be there).
However, local and systemic responses may be achieved at 
the same time when radiotherapy is combined rationally with 
immunotherapy. Indeed, the Demaria/Formenti groups first 
demonstrated that radiotherapy combined with anti-CTLA-4 
improved control of irradiated tumors and reduced non-irradiated 
lung metastases in preclinical models (61, 62). Similarly, PD-L1 
or PD-1 blockade and radiotherapy-induced local combined 
responses in mouse models for colon carcinoma (MC38) and 
mammary tumors (4T1 and TUBO) (63), and resulted in long-
term survival in a mouse model for intracranial gliomas (GL261) 
(64). In the latter case, long-term immunologic memory was 
achieved, because rechallenged, long-term surviving mice did 
not develop new tumors.
A number of clinical case studies showed that concurrent 
treatment with radiotherapy and anti-CTLA-4 (ipilimumab) 
promoted an abscopal effect in metastatic melanoma (3 × 9.5 Gy) 
as well as in NSCLC (5 × 6 Gy in 10 days) (65, 66). However, 
it is unclear whether this effect is caused by the combination 
of radiotherapy and anti-CTLA-4 (systemic effect of combina-
tion) or anti-CTLA-4 alone (systemic effect of immunotherapy), 
since the latter control was obviously not included in these case 
studies.
Confirming the challenge of obtaining systemic combined 
effects between radiotherapy and aCTLA-4 comes from a 
phase  I/II study with castration-resistant prostate cancer 
(CRPC) patients, in which the tumors were first irradiated 
(1 × 8 Gy), followed by anti-CTLA-4 (ipilimumab) administra-
tion 2 days later in an attempt to maximize antigen presentation 
(67). In this study, relatively few severe adverse events (10%) 
were reported and a complete response occurred. However, no 
differences in median survival were found in a phase III trial 
among metastatic CRPC patients applying radiotherapy plus 
anti-CTLA-4 (ipilimumab) or placebo (11.2 versus 10.0 months) 
(68), again indicating that systemic combined effects between 
radiotherapy and anti-CTLA-4 are sub-optimal. Finally, a 
recent phase I study in metastatic melanoma patients reported 
an 18% abscopal response rate, but this is also expected from 
anti-CTLA-4 treatment alone (69). Anti-CTLA-4 treatment can 
result in the upregulation of tumoral PD-L1 expression (69). 
Indeed, the addition of anti-PD-1 or anti-PD-L1 to radiotherapy 
plus anti-CTLA-4 in a mouse model increased local combined 
responses and achieved cures in up to 80% of the animals, but 
combined effects on non-irradiated tumors were not assessed in 
this setting (69).
Hence, high (local) response rates are currently only achieved 
in combination with double immune-checkpoint blockade, 
and convincing clinical abscopal effects with radiotherapy and 
immune-checkpoint blockade are yet to be reported. In  order 
to optimize the efficacy of combination approaches with 
radiotherapy, it is important to mechanistically understand how 
radiotherapy can optimally induce ICD to kickstart a new T cell 
response, which likely depends on the tumor type and location 
(hypoxic versus normoxic environment) and how irradiated and 
distal tumor-microenvironment are influenced by radiotherapy. 
Then, irradiation dose, scheduling, size of radiotherapy field 
(note: want this as small as possible to prevent damage to circulat-
ing lymphocytes that circulate through the RT field), timing, and 
delivery method can be optimized to achieve local and systemic 
therapeutic effects with immune-checkpoint inhibitors (70–72). 
For more details on preclinical and clinical efficacy of radio-
therapy combined with aCTLA-4 see an elegant, recent review by 
Vanpouille-Box et al. (73).
In summary, the preclinical studies on combination 
approaches of immune-checkpoint blockade with stimulation of 
antigen release are promising, yet the clinical efficacy is currently 
limited. Furthermore, combination therapies with chemotherapy 
of BRAF-targeted therapies are potentially accompanied by 
severe side effects. Combination approaches with radiotherapy 
seem to have a more favorable toxicity profile, but, to date, local 
and abscopal antitumor responses are limited.
COMBiNATiONS wiTH STiMULATiON 
OF ANTigeN PReSeNTATiON AND  
CO-STiMULATiON (STeP 2)
Peptide vaccines, live attenuated vaccines, cellular vaccines, 
oncolytic viruses, and agonists for co-stimulatory molecules on 
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antigen-presenting cells (APCs), such as DCs, can be used to 
stimulate antigen presentation.
Peptide
In a phase I study with advanced melanoma patients, vaccina-
tion with a modified sequence from glycoprotein 100 (gp100), a 
melanoma tumor antigen, increased the frequency of melanoma-
specific CD8+ T cells (74). Nevertheless, the tumors progressed, 
implying that vaccination may benefit from combination with 
immune-checkpoint blockade. However, anti-CTLA-4 (ipili-
mumab) plus gp100 peptide vaccine did not improve the OS, 
compared with anti-CTLA-4 alone (10.0 versus 10.1  months) 
in a phase III trial in advanced melanoma patients (9). Thus, 
multiple antigens may need to be targeted to induce sufficient 
antitumor CD8+ T cell responses. Such a multi-peptide vaccine 
(gp100, MART-1, NY-ESO-1) increased the number of gp100+, 
MART-1+, and NY-ESO-1+ CD8+ T cells in advanced melanoma 
patients when combined with anti-PD-1 (nivolumab), and a 
promising 1-year survival of 87% was obtained in this phase I 
trial (75). Thus, early clinical data indicate that multi-peptide 
vaccines combined with immune-checkpoint blockade are 
highly promising.
Live Attenuated vaccines
Vaccination strategies in combination with immune-checkpoint 
blockade are also studied in non-melanoma tumors. Currently, 
a vaccine with a live-attenuated Listeria strain encoding the 
human papillomavirus (HPV) 16 oncoprotein E7 (ADXS11-
001) in combination with anti-PD-L1 (durvalumab) is studied 
in a phase I/II trial in patients with cervical cancer or HPV-
positive head and neck cancer (NCT02291055). Furthermore, 
a live-attenuated Listeria strain encoding for prostate-specific 
antigen level (PSA) (ADXS31-142) in combination with 
anti-PD-1 (pembrolizumab) is studied in a phase I/II trial in 
patients with prostate cancer (NCT02325557). In summary, 
combination approaches with live attenuated viruses are cur-
rently tested in the clinic, but clinical safety and efficacy data 
are not available yet.
Cellular vaccines
Clinical trials combining checkpoint therapy with cellular vaccines 
are also ongoing, such as a phase I trial combining MART-126–35-
loaded DC injection with anti-CTLA-4 (tremelimumab) in meta-
static melanoma patients (76) and with anti-PD-1 (nivolumab) in 
patients with recurrent brain tumors (NCT02529072).
However, cellular vaccines consisting of irradiated GM-CSF-
producing tumor cells (GVAX) may be more suitable, since they 
deliver multiple antigens. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) attracts DCs, stimulates the 
differentiation of monocytes into DCs, and amplifies DC cell 
maturation and antigen presentation (77, 78). Preclinical stud-
ies showed that subcutaneous injection of GVAX plus CTLA-4 
blockade synergistically promoted tumor eradication in the 
B16 mouse melanoma model (response rate 80 versus 16% with 
GVAX alone) (79) due to an increase in CD8+ T cells and in 
effector T cell/Treg ratio in the tumor (80). GVAX plus PD-1 
blockade also enhanced survival in the murine B16 melanoma, 
CT26 colon carcinoma, and pancreatic ductal adenocarcinoma 
models (81, 82). Furthermore, GVAX plus double checkpoint 
blockade (anti-CTLA-4 and anti-PD-1) enhanced tumor rejec-
tion to 100% in CT26 colon carcinoma and to 75% in ID8 
ovarian carcinoma, compared to, respectively, 75 and 50% with 
double checkpoint blockade only (83). It should be noted that 
depigmentation was observed in 56% of the mice after com-
bined GVAX and immune-checkpoint blockade (79), which 
correlated with antitumor activity. Clinical studies with cellular 
vaccines and checkpoint therapy are still rare. In a phase I/II 
trial with metastatic CRPC patients, treatment with GVAX plus 
anti-CTLA-4 (ipilimumab) was found to be safe and decreased 
the PSA by ≥50% in 25% of the patients (84). Thus, preclinical 
and early clinical data of cellular vaccines in combination with 
immune-checkpoint blockade are promising, warranting future 
clinical studies.
gM-CSF and Oncolytic viruses
Granulocyte-macrophage colony-stimulating factor can also be 
directly administered instead of through production by irradi-
ated tumor cells. In a phase II trial of systemic administration 
of recombinant GM-CSF (sargramostim) plus ipilimumab in 
metastatic melanoma patients, their 1-year survival increased 
upon combination therapy compared with anti-CTLA-4 alone 
(68.9 versus 52.9%) without toxicity differences (85). In addi-
tion, to minimize toxicity and optimize efficacy, GM-CSF can 
also be locally delivered in the tumor using modified oncolytic 
herpes viruses (talimogene laherperepvec; T-VEC) to produce 
GM-CSF. Such oncolytic viruses infect melanoma cells and then 
directly promote cell death with antigen release, stimulating 
antitumor immune responses (86). Intratumoral injection of 
T-VEC in melanoma patients in combination with ipilimumab 
treatment resulted in a response rate of 50% with a tolerable 
safety profile in a phase Ib trail. Currently, T-VEC combined 
with anti-CTLA-4 (ipilimumab) is studied in a phase II trial 
(NCT01740297) and combined with anti-PD-1 (pembroli-
zumab) in a phase Ib/III trail (NCT02263508), both in mela-
noma patients. The latter provided a clinical benefit and a phase 
III trial is planned (87, 88). Based on the clinical response rate 
of T-VEC and anti-CTLA-4, immune-checkpoint blockade with 
oncolytic viruses might be one of the most promising combina-
tion approaches.
Anti-CD40 and Anti-CD47
CD40 is constitutively expressed on APCs and, like GM-CSF, 
agonistic antibodies for CD40 (anti-CD40) provoke DC matura-
tion and the expression of co-stimulatory molecules. A 27.3% 
response rate was obtained with anti-CD40 (CP-870893) plus 
anti-CTLA-4 (tremelimumab) in a phase I study in melanoma 
patients (NCT01103635) (89). As anti-CD40 has been shown 
to upregulate PD-L1 in a mouse model (90), higher response 
rates might be obtained with anti-CD40 plus anti-PD-1. Indeed, 
anti-CD40 (APX005M) is currently studied in combination with 
anti-PD-1 (pembrolizumab) in a phase I/II trial in melanoma 
patients (NCT02706353). Furthermore, combination therapies 
with antagonistic antibodies for CD47, which provide “do not 
eat me” signals to APCs, might be used in the future in order 
TABLe 1 | Preclinical studies double or triple immune-checkpoint blockade.
Combination Tumor model Response monotherapy Response combination therapy Reference
Anti-CTLA-4 IDOi (1MT) B16F10 20 and 0% OS 55% OS (102)
B16.SIY 0 and 0% CR 18.8% CR (103)
Anti-PD-1  
(or anti-PD-L1)
IDOi (1MT) B16.SIY 0 and 0% CR 13.3% CR (103)
Anti-LAG-3 As1N 20 and 10% CR 70% CR (101)
B16 0 and 0% CR 0% CR (101)
MC38 40 and 0% CR 80% CR (101)
Anti-TIGIT CT26 0 and 10% OS 70% OS, 75% decrease TV (100)
EMT-6 – 75% decrease TV (100)
Anti-TIM3 CT26 0 and 0% CR 50% CR (104)
GL261 ? and 0% OS 60% OS (105)
Anti-VISTA CT26 37.5 and 12.5% OS 100% OS (106)
Anti-CTLA-4+ anti-PD-1  
(or anti-PD-L1)
– B16 10 and 25% OS 50% OS (92)
B16.SIY 0 and 0% CR 55.5% CR (103)
K7M2 0 and 0% OS 60% OS (93)
IDOi (1MT) GL261 90 and 20% OS 100% OS (107)
B16.SIY 55.5 and 0% CR 55.5% CR (103)
Note that the response data are not meant for direct comparison among the various preclinical models, but are merely presented to give an overview.
CR, complete respone; OS, overall survival; TV, tumor volume; TG, tumor growth.
The question mark indicates that the effect of anti-PD-1 was not assessed in this study.
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to stimulate the engulfment of antigens (91). Thus, combina-
tion approaches with anti-CD40 or anti-CD47 can also be 
used to improve antigen presentation, but the available data 
show a smaller effect than other approaches to affect antigen 
presentation.
Overall, both the preclinical and initial clinical data for com-
bination therapy with immune-checkpoint blockade and multi-
peptide vaccines and oncolytic viruses are promising, whereas the 
combination with single peptide vaccines and anti-CD40 so far 
seem less effective.
COMBiNATiONS wiTH STiMULATiON OF 
T CeLL ACTivATiON (STeP 3)
Combination approaches of anti-CTLA-4 or anti-PD-1 with the 
blockade of other immune-checkpoints or with activation of 
co-stimulatory molecules may also further amplify antitumor 
immune responses.
Double immune-Checkpoint Blockade
CTLA-4 plus PD-1 Blockade
Preclinical models revealed that blocking of CTLA-4 or 
PD-1 alone led to upregulation of the unblocked pathway 
(92); hence, the efficacy of either monotherapy is limited by 
increased suppression of T cell responses through the other of 
the two pathways. Indeed, combined blockade of CTLA-4 and 
PD-1 prolonged survival in a B16 melanoma model (92), and 
combined PD-L1 and CTLA-4 blockade prolonged disease-free 
survival in the K7M2 model for metastatic osteosarcoma (93). 
This was due to enhanced effector T cell infiltration, prolifera-
tion, inflammatory cytokine production (e.g., IFN-γ), and an 
increase in the ratio of CD8+ T cells to Tregs and MDSCs in the 
tumor (92, 94).
Phase II clinical trials involving combination treatment with 
anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) resulted 
in a higher response rate (61 versus 11% with anti-CTLA-4 
only), more complete responses (22 versus 0% with anti-CTLA-4 
only), and higher PFS in a phase III trial (11.2; anti-CTLA-4 
2.9; anti-PD-1 6.9  months) (95, 96). However, severe (grade 3 
or 4) treatment-related autoimmune adverse events were also 
amplified (55%; anti-CTLA-4 27.3%; anti-PD-1 16.3%) (96). In 
2015, these studies led to the accelerated approval of anti-CTLA-4 
(ipilimumab) in combination with anti-PD-1 (nivolumab) for the 
treatment of unresectable or metastatic melanoma in the USA. 
Still, optimization of this combination therapy, other combina-
tion approaches, or an individualized treatment is required to 
obtain clinical responses in a fraction of the patients above the 
current 60%. Currently, a phase I/II trial combining anti-CTLA-4 
and anti-PD-1 therapy is ongoing in patients with solid tumors or 
sarcomas (NCT02304458), which will provide information about 
the efficacy and safety of double immune-checkpoint blockade 
in tumor types other than melanoma. Overall, double immune-
checkpoint blockade with anti-CTLA-4 anti-PD-1 is currently 
the most effective combination approach and is approved for 
the treatment of melanoma.
Novel Immune Checkpoints
The immune-checkpoint molecules lymphocyte-activation gene-3 
(LAG-3), T cell ITIM domain (TIGIT), or T cell immunoglobulin 
and mucin domain-3 (TIM-3) may also contribute to the immune 
evasion of tumor cells because they are primarily expressed on 
exhausted T cells (97–100). Various combinations have been 
tested in mouse models (Table  1). Blocking PD-1 and LAG-3 
is particularly interesting because both are mainly expressed on 
TILs (101), which may result in a favorable safety profile due to 
restriction of T cell responses to the tumor-microenvironment. 
Results for this combination were promising in fibrosarcoma and 
colon cancer models, but tumor growth in the B16 melanoma 
model was not affected (101), possibly due to low LAG-3 and 
PD-1 expression on TILs in the B16 model. These observations 
highlight the importance to establish biomarkers that predict 
treatment responses to these combination approaches.
TABLe 2 | Preclinical studies immune-checkpoint blockade plus co-stimulation.
Combination Tumor model Response monotherapy Response combination therapy Reference
Anti-CTLA-4 CD137 CL261 0 and 0% OS 18% OS (116)
ID8 No effect No effect (117)
MC38 14 and 14% CR 86% CR (115)
B16F1/F10 No effect No effect (115, 118)
OX40 ID8 0 and 0% OS 60% OS (112)
MCA-205 18 and 22% OS 75% OS (113)
TRAMP-C1 20 and 18% OS 75% OS (113)
CD27 TC-1 0 and 50% OS 50% OS (119)
Anti-PD-1 CD137 B16F10 No effect 85% decrease TG (120)
CT26 0 and – CR 100% CR (121)
ID8 No effect Median survival + 30 days (117)
GITR ID8 0 and 0% OS 20% OS (114)
CD27 TC-1 0 and 50% OS 100% OS (119)
Note that the response data are not meant for direct comparison among the various preclinical models, but are merely presented to give an overview.
CR, complete respone; OS, overall survival; TV, tumor volume; TG, tumor growth.
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Furthermore, the inhibitory ligand V-domain immunoglobu-
lin (Ig)-containing suppressor of T cell activation [VISTA, also 
known as PD-1 homolog (PD-1H)] is expressed on hematopoi-
etic cells (e.g., T cells) and in particular on myeloid cells in tumors 
(108–110). The combination of anti-VISTA and anti-PD-1 syner-
gistically promoted regression and long-term survival in a colon 
carcinoma (CT26) model (106). Therefore, it would be interesting 
to test this combination in the clinic.
In addition to T cell immune checkpoints, NK cells express 
killer-cell immunoglobulin-like receptors (KIRs), which inhibit 
the cytotoxic activity of NK cells after interaction with MHC-I 
on tumor cells (111). Co-blockade of PD-1 or CTLA-4 and KIR 
might be beneficial due to the activation of both T- and NK 
cells. Currently, the effect of combination therapy with anti-
KIR (lirilumab) and anti-PD-1 (nivolumab; NCT01714739) or 
anti-CTLA-4 (ipilimumab; NCT01750580) are investigated in 
phase I clinical studies in patients with advanced solid tumors. 
In summary, combination therapies with novel immune check-
points might have a more favorable safety profile compared to 
anti-CTLA-4 with anti-PD-1, and clinical assessment of these 
approaches is needed.
Co-Stimulatory Molecules
Like immune-checkpoint blockade, agonistic antibodies for 
 co-stimulatory molecules (e.g., CD27, CD137, GITR, and OX40) 
amplify T cell activation and, as a consequence, they may also 
enhance antitumor T cell responses. Various combinations 
with checkpoint blockade have been tested in mouse models 
(Table  2). The combination of OX40 and anti-CTLA-4 is syn-
ergistic in ovarian carcinoma (ID8), fibrosarcoma (MCA-205), 
and prostate cancer (TRAMP1) models (112, 113). Moreover, 
anti-GITR and anti-PD-1 have synergistic effects in the ID8 
model (114). Some of these combinations have potentially less 
autoimmune side effects than double immune-checkpoint block-
ade while still having beneficial effects, for example, combination 
therapy involving anti-CD137 and CTLA-4 blockade in MC38 
colon carcinoma tumors and GL261 glioblastoma (115, 116). 
In contrast, this combination treatment had no effect on B16 
melanoma tumors (115, 116), which may be due to increased 
PD-L1 expression on those tumors.
Since PD-L1 expression can confer resistance to anti-CD137 
treatment (122), combined CD137 activation and PD-1 
rather than CTLA-4 blockade may further improve antitumor 
responses. Indeed, anti-CD137 plus anti-PD-1 resulted in 
increased efficacy in mouse models for colon carcinoma (ID8), 
melanoma (B16F10), and ovarian carcinoma (ID8) (117, 120, 
121). Furthermore, triple therapy (activation of CD137 and 
blockade of PD-1 and CTLA-4) was even more effective in the 
ID8 model (117). However, CD137 agonists have been reported 
to induce severe liver inflammation (123, 124), and, therefore, 
more studies determining the toxic effects of combinations 
involving such agonists are needed. Moreover, intratumoral 
administration may help to minimize liver toxicity. Although 
liver inflammation was not detected in combination with 
anti-CTLA-4 or anti-PD-1 in preclinical studies (115, 117, 
120), caution should be taken during its clinical assessment. 
Currently, a phase I study, in which the toxicity of anti-CD137 
and anti-PD-1 is determined in patients with solid tumors, is 
in progress (NCT02179918). Combination approaches with 
anti-CD27 (Tnfrsf7) are also promising (125). The combination 
of anti-CD27 with anti-PD-1, but not anti-CTLA-4, eradicated 
tumors in a cervical cancer model (TC-1) (119). Currently, 
the combination of anti-CD27 (varlilumab) with anti-CTLA-4 
(ipilimumab) or anti-PD-1 (nivolumab) is investigated in 
respectively patients with melanoma (NCT02413827) and solid 
tumors (NCT02335918) in phase I/II studies. Like the combina-
tion approaches with blockade of novel immune checkpoints, 
agonists for co-stimulatory molecules might have a more favora-
ble safety profile, but caution is required with anti-CD137.
Summarizing the combinations with T cell stimulation, dou-
ble immune-checkpoint blockade of CTLA-4 and PD-1 dramati-
cally increased the response rate compared with monotherapy, 
but personalized treatment of anti-PD-1 with new immune-
checkpoint inhibitors or agonists for co-stimulatory molecules 
can potentially minimize the severe side effects observed with 
CTLA-4/PD-1 combined blockade.
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COMBiNATiONS wiTH 
TRAFFiCKiNg iNHiBiTiON OF 
Tregs OR MSDCs (STeP 4)
Apart from recruiting antitumor T cells in step 4 of the cancer-
immunity cycle, tumors also attract MDSCs and Tregs, which 
contribute to evasion of immune destruction. Therefore, traffick-
ing inhibition of MDSCs and Tregs to the tumor using specific 
chemokine receptor inhibitors could abrogate immune evasion 
and improve antitumor T cell responses. Subpopulations of 
MDSCs express high levels of C–C chemokine receptor 1 (CCR1) 
or CXC chemokine receptor 2 (CXCR2) (126, 127). Their ligands, 
respectively, CCL5 (MCP-1), CCL7 (RANTES), and CXCL8, are 
secreted by tumors and mediate the recruitment of CCR1 or 
CXCR2 positive MDSCs. Combination of a CCR1 antagonist 
(CCX9588) and anti-PD-L1 synergistically reduced the tumor 
burden in a preclinical breast cancer model (126). Moreover, 
anti-CXCR2 plus anti-PD-1 enhanced survival in a rhabdomyo-
sarcoma (RMS) model (127).
Regulatory T cells (FOXP3hi and CD45RA−) express high 
levels of CCR4 in the blood and inside tumors (128). Therefore, 
combination approaches of immune-checkpoint blockade and 
inhibition of Treg recruitment employing anti-CCR4 is promis-
ing. In addition, anti-CCR4 promotes antibody-dependent cell-
mediated cytotoxicity (ADCC), which may further reduce the 
Treg population (129). Currently, anti-CCR4 (mogamulizumab) 
in combination with anti-PD-1 (nivolumab; NCT02705105, 
phase I/II), anti-PD-L1 (durvalumab; NCT02301130, phase I), 
and anti-CTLA-4 (tremelimumab; NCT02301130, phase I) is 
being tested in the clinic in patients with various advanced solid 
tumors. In summary, preclinical studies indicate the potential of 
trafficking inhibition of Tregs or MDSCs, but clinical efficacy data 
are not reported yet.
COMBiNATiONS wiTH T CeLL 
iNFiLTRATiON STiMULATORS (STeP 5)
Deficient T cell infiltration can contribute to tumor immune 
escape because of the absence of sufficient numbers of T cells. T 
cell infiltration can be stimulated using anti-VEGF, agonists for 
innate immune receptors, and epigenetic modification.
vascular endothelial growth Factor
The growth factor VEGF inhibits T cell infiltration into the 
tumor by downregulation of adhesion molecules on endothelial 
cells (130). However, the immunosuppressive function of VEGF 
is much more diverse. For instance, VEGF also inhibits antigen 
presentation by DCs, enhances the expansion of Tregs, and medi-
ates PD-1 upregulation on tumor-infiltrated T cells (131–133). 
High VEGF levels are associated with decreased OS in advanced 
melanoma patients after treatment with anti-CTLA-4 (134). 
Therefore, the combination of anti-VEGF-A (bevacizumab; 
humanized IgG1, Roche) and anti-CTLA-4 (ipilimumab) was 
investigated in a phase I trial in advanced melanoma patients. 
This combination resulted in a high CD8+ T cell infiltration and 
a median survival of 25.1 months (135), suggesting a substantial 
benefit compared to the 10.1  months median survival of anti-
CTLA4 alone (9) (note though that this is another trial). In this 
trial, 28.3% of the patients experienced severe (grade 3 or 4) 
adverse events (135).
Another phase I trial applying a small molecule tyrosine kinase 
VEGF receptor (VEGFR) inhibitor (sunitinib) plus anti-CTLA-4 
(tremelimumab) to patients with metastatic RCC resulted in 
acute renal failure, and the study was therefore halted (136). 
However, combined treatment with the generally safer anti-PD-1 
and the VEGFR inhibitor sunitinib may be feasible. In pre-
clinical studies, the combination of anti-VEGF-A and anti-PD-1 
therapy was more effective than the monotherapies in a CT26 
carcinoma mouse model (131). Moreover, preliminary clinical 
data of a phase I trial investigating the combination of anti-PD-1 
(nivolumab) with either the VEGFR inhibitor sunitinib or with 
a multikinase VEGFR inhibitor (pazopanib) are promising (137, 
138). In summary, combination therapies with anti-VEGF might 
provide a substantial survival benefit to patients, whereas caution 
is required with VEGFR inhibitor combination therapies due to 
renal toxicity.
innate immune Receptors
Innate immune receptors (also known as pattern recognition 
receptors; PRR) such as TLR can detect a broad range of pathogen- 
and danger-associated patterns. Binding of these ligands to TLRs 
on DCs results in their maturation (139, 140). In addition, TLR9 
agonists have been shown to increase T cell infiltration in the 
CT26 colon cancer model (141). Therefore, TLR9 agonists might 
be used to enhance T cell infiltration into the tumor. Currently, 
anti-CTLA-4 (ipilimumab) combined with a TLR9 agonist 
(MGN1703) is studied in a phase I trial in patients with advanced 
solid malignancies (NCT02668770). In summary, although clini-
cal data are not yet available, combinations with innate immune 
receptor stimulation might improve T cell infiltration.
epigenetic Modulation
Epigenetic silencing of immune-related genes using hyper-
methylation contributes to immune evasion during tumor 
progression (142, 143). Hypomethylating agents, of which the 
nucleoside DNA methylation inhibitor Azacitidine (AZA) and 
5-aza-2′-deoxycitidine (5AZA2) are most extensively studied, 
can be used to restore gene expression (144). 5AZA2 treatment 
has been shown to promote CD8+ T cell infiltration into the 
tumor in the EL4 lymphoma model, which was attributed to 
demethylation-induced CD80 expression on tumor cells (145). 
Therefore, hypomethylation can be used as a strategy to stimulate 
T cell infiltration into the tumor. Moreover, 5AZA2 treatment 
combined with anti-CTLA-4 is synergistic in murine mammary 
carcinoma TS/A and in mesothelioma AB1 models and results in 
high CD8+ and CD4+ T cell infiltration (146). Thus, clinical stud-
ies are needed as a next step to investigate the safety and efficacy 
of combination approaches with epigenetic modulation.
In conclusion, several approaches to stimulate T cell infiltra-
tion have been attempted but our knowledge on the efficacy of 
T cell infiltration stimulators combined with checkpoint block-
ade remains limited. This clearly is an area where more research 
is needed.
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COMBiNATiONS wiTH ANTigeN 
ReCOgNiTiON STiMULATORS (STeP 6)
Adoptive cell transfer is another promising strategy for the treat-
ment of melanoma with objective response rates of approximately 
50% and complete tumor regression in 22% of the patients (147). 
This approach involves the ex vivo culture of a tumor biopsy, 
the expansion and selection of TILs for tumor specificity, and 
reinfusion of the tumor-reactive cells into the patient. Instead 
of TILs, T cells expressing antigen-specific chimeric antigen 
receptors (CARs) are alternatively used to target specific tumor 
antigens (148). However, the lack of sufficient T cell infiltra-
tion into the tumor, as well as an immunosuppressive tumor-
microenvironment may limit ACT success in some patients 
(149). Indeed, ACT plus anti-PD-1, anti-PD-L1, or anti-CTLA4 
synergistically reduced tumor growth in the MC38 carcinoma, 
B16 and B16F10 melanoma mouse models (150–152) and 
increased the long-term survival in transgenic Her-2 mice upon 
ACT of Her-2+-specific CAR T cells and anti-PD-1 compared 
to the monotherapies (153). Combination therapy enhanced the 
proliferation of T cells within tumors, their cytotoxic activity, 
and IFN-γ production, which mediated chemokine upregulation 
(e.g., CXCL10) and further T cell infiltration (150). Thus, the 
application of immune-checkpoint blockade after ACT may 
result in complete tumor regression in a large population in the 
clinic. Currently, the combination of ACT and anti-CTLA-4 is 
studied in a phase II study in patients with metastatic melanoma 
(NCT02027935).
Because anti-CTLA-4 and anti-PD-1 promote intratumoral 
T cell infiltration, immune-checkpoint blockade prior to ACT 
may increase the number of TILs that can be derived from a 
tumor biopsy. Moreover, expanded TILs derived from anti-
CTLA4-treated patients have a less exhausted phenotype, which 
is associated with improved clinical responses (154). In sum-
mary, applying immune-checkpoint blockade either before or 
after ACT is a promising approach, but clinical data are currently 
lacking.
COMBiNATiONS THAT iNCReASe  
TUMOR KiLLiNg (STeP 7)
As discussed, tumor cells can evade killing via PD-L1 expression, 
since the interaction of PD-L1 with PD-1 inhibits the secretion 
of cytotoxic mediators by CD8+ T cells (2). Moreover, other 
molecules expressed on APCs or tumor cells may limit killing, 
such as indoleamine 2,3-dioxygenase (IDO), or immune sup-
pressive mediators accumulating in the tumor environment, like 
adenosine and transforming growth factor β (TGF-β). Note that 
also the earlier discussed approaches of chemo- and radiotherapy 
can help to sensitize tumor cells to T cell-induced death.
Adenosine
Adenosine inhibits T cell proliferation and cytotoxicity upon 
binding to the A2A receptor on T cells (155–157). In addition, 
adenosine can directly provoke metastasis upon interaction with 
the A2B receptor on tumor cells (158). As a consequence, the 
combination of an A2A receptor antagonist and anti-CTLA-4 or 
anti-PD-1 synergistically inhibited (metastatic) tumor growth in 
breast cancer (4T1) and melanoma (B16F10) preclinical models 
(159–161). Currently, the safety and tolerability of combined A2A 
receptor antagonist (CPI-444) and anti-PD-L1 (atezolizumab) 
treatment is studied in a phase I trial in advanced cancers 
(NCT02655822).
Adenosine is formed by dephosphorylation of adenosine 
monophosphate (AMP) by the ecto-enzyme CD73 (162). Thus, 
CD73 has an immunosuppressive and pro-metastatic effect. 
Moreover, CD73 stimulates angiogenesis through upregulated 
VEGF secretion by tumor cells (163). As a consequence, high 
expression of the enzyme CD73 is associated with a poor prognosis 
in various cancer types (164–166). This enzyme is also a potential 
biomarker for anti-PD-1 therapy, since CD73 expression limits 
anti-PD-1 efficacy (161, 167). Indeed, both combined treatment 
with anti-CD73 and anti-CTLA-4 or anti-PD-1 enhanced the 
antitumor activity in colon (MC38), prostate (RM-1), and meta-
static breast cancer (4T1.2) models (168). Currently, the combi-
nation of anti-CD73 (MEDI9447) plus anti-PD-L1 (durvalumab) 
is investigated in the clinic in patients with advanced solid cancer 
(NCT02503774) in a phase I study. In summary, combination 
approaches with A2A receptor antagonists and anti-CD73 to 
improve tumor killing are currently studied in the clinic due to 
their success in preclinical studies.
Transforming growth Factor-β
Transforming growth factor-β can also contribute to immune 
suppression by stimulating Tregs (169). Preclinically, combined 
treatment with a TFG-β receptor kinase inhibitor I and anti-
CTLA-4 synergistically inhibited primary and metastatic tumor 
growth in a melanoma model (BRAFV600EPTEN−/−) (170). The 
combination of the TFG-β receptor kinase inhibitor I (galunis-
ertib) and anti-PD-L1 (durvalumab) or anti-PD-1 (nivolumab) 
are currently being clinically tested in patients with metastatic 
pancreatic cancer (NCT02734160, phase I) and NSCLC, hepato-
cellular carcinoma, or glioblastoma (NCT02423343, phase I/II). 
These clinical studies will demonstrate if combination approaches 
with TGF-β receptor kinase inhibitors may improve the treatment 
of various tumors.
In addition, TGF-β may impair radiotherapy-induced T cell 
priming, and TGF-β blocking antibodies can enhance T cell 
priming (step 2–3) and promote abscopal responses induced by 
(fractionated) radiotherapy in the 4T1 mouse model (53).
iDO
The presence of the tryptophan degrading enzyme IDO on APCs 
or tumor cells may also limit the killing efficacy of CTLA-4 or 
PD-1 blockade because tryptophan is required for T cell prolif-
eration (171). Indeed, several preclinical studies demonstrated a 
survival benefit of combinations of anti-CTLA-4 or anti-PD-L1 
with IDO inhibition by 1-methyl-d-tryptophan (1MT) treatment 
(Table  1). Thus, combination approaches with IDO inhibition 
may be efficacious, especially in patients with a high IDO expres-
sion. Finally, triple immune-checkpoint blockade of CTLA-4, 
PD-1, and IDO could further improve antitumor responses, 
but this approach probably does not increase the effectiveness 
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compared to double checkpoint blockade in more established 
tumors (107).
Early clinical safety and efficacy data for the IDO1 inhibitor 
(epacadostat) in combination with anti-PD-1 (pembrolizumab) 
were promising for the treatment of various advanced cancers 
in a phase I/II study (e.g., melanoma, RCC, and NSCLC) (172). 
Currently, the IDO inhibitor epacadostat is also being tested 
in combination with anti-PD-1 (nivolumab; NCT02327078) 
and anti-PD-L1 (durvalumab; NCT02318277) for various 
cancers in phase I/II studies. In addition, 1MT (indoximod) 
plus anti-CTLA-4 (ipilimumab) or anti-PD-1 is being tested 
in melanoma patients (NCT02073123) in a phase I/II study. 
Thus, both preclinical and early clinical studies involving IDO 
inhibition have yielded promising results. However, because 
IDO inhibition seems particularly effective in tumors with a 
high IDO expression, it would be useful to target these patients 
specifically.
Summarizing the approaches that stimulate killing by T cells, 
various clinical trials currently investigate combination therapies 
that enhance such killing, but to date clinical safety and efficacy 
data are limited.
CONCLUSiON
Various combination approaches with immune-checkpoint 
blockade have been studied in preclinical models, but to date 
the clinical efficacy and toxicity data are limited. It is difficult 
to compare the efficacy of the preclinical studies, since various 
cell lines and tumor models are used. A step forward here would 
be to employ a combination of experimental approaches and 
mathematical modeling to quantify the CTL-mediated killing 
rates (173, 174) for tumor destruction in different settings (i.e., 
tumor models, treatments) as well as the variability of these rates 
among mice, taking into account factors such as T cell infiltration 
and tumor size.
Double immune-checkpoint blockade or combinations with 
agonists for co-stimulatory molecules are effective at amplify-
ing T cell activation. High response rates have especially been 
obtained by the combination of CTLA-4 and PD-1 and as a 
consequence this combination was approved in 2015 for the 
treatment of melanoma. Nevertheless, these approaches are 
not effective in all patients. Preclinical data suggest that com-
plete tumor regression may be achieved in a large part of the 
population after combined treatment with ACT and immune-
checkpoint blockade, but its widespread employment may be 
limited due to extensive laboratory requirements and the high 
costs involved. Initial clinical data also indicate that combina-
tion approaches with multi-peptide vaccines are effective, but 
patients with non-melanoma tumors expressing low levels of 
tumor antigens do not benefit from such an approach. In order to 
improve the efficacy of immune-checkpoint blockade in patients 
with non-melanoma tumors, combinations with chemotherapy 
or targeted therapies may be effective, since they induce antigen 
release and provide danger signals, but the adverse effects are 
often severe. Combined double immune-checkpoint blockade 
and radiotherapy might be a promising combination therapy 
in case the abscopal responses can be optimized (Figure  1). 
Moreover, the optimal timing of immune-checkpoint blockade 
relative to the “backbone” radiotherapy needs to be determined. 
Although combination approaches can increase the fraction of 
patients that respond to treatment in various cancer types, indi-
vidualized immune-checkpoint combination approaches, based 
on predictive biomarkers, has an even higher potential to ensure 
that each patient is provided with the optimal care. Therefore, 
establishing biomarkers specifically for combination therapies 
involving immune-checkpoint blockade has high priority in 
future research.
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